Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Summary not available.
Philips (NYSE: PHG) received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, designed to improve pulse oximetry reliability across diverse patient populations and clinical conditions. The sensor uses internal optical refinements to enhance signal quality and measurement consistency.
In desaturation studies, the sensor achieved an Accuracy Root Mean Square (ARMS) of 1.6%, compared with the 3% level recommended by ISO and recognized by the FDA. Accuracy varied by less than 0.5% between light and dark skin pigmentation groups in an SaO₂ range of 85–100%. The device is supported by Philips’ validation program aligned with FDA guidance and ISO/IEC standards and will be introduced in select global markets later this year. Philips reported 2025 sales of EUR 18 billion and operates in more than 100 countries.
Philips (NYSE:PHG) launched the Alturion ultrasound system, featuring AI-powered workflows for high-volume clinical environments. Alturion recently received FDA 510(k) clearance and CE mark, enabling availability in the USA and Europe.
The system offers advanced imaging, Elevate Plus AI measurements, and integration within Philips’ connected ultrasound ecosystem, sharing a common interface and interchangeable transducers with EPIQ Elite and Affiniti systems. Compatibility with Collaboration Live supports real-time remote ultrasound support, training and consultation across care settings.
Philips (NYSE:PHG) unveiled the Philips Sonicare Next-Generation DiamondClean 9900 Prestige, its most advanced electric toothbrush with on-device AI guidance, real-time light ring feedback, and a 12-segment mouth map. It targets better plaque removal and gum health, quieter performance, and eco-minded design, launching on Amazon in September 2026.
Philips (NYSE:PHG) signed a long-term strategic contract with University Health in San Antonio to modernize and standardize patient monitoring using its Enterprise Monitoring as a Service (EMaaS) model.
The deal implements a unified platform including the Central Monitoring Unit, IntelliVue monitors, transport and wearable devices, and data analytics tools to support alarm management, continuous surveillance and scalable, data-driven care across one of Texas’ largest public health systems.
Philips (NYSE:PHG) introduced the IntelliVue Patient Monitor 6000 Series, a full monitoring solution aimed at rural hospitals, ambulatory surgery centers and other U.S. providers needing affordable, enterprise-grade capabilities.
The PM 6000 Series offers built-in core measurements, easy expansion, scalable connectivity and compatibility with existing IntelliVue MX ecosystems.
Philips (NYSE:PHG) released its 2026 Future Health Index U.S. report showing AI moving into daily clinical practice. 36% of clinicians say AI lets them see more patients, with a median of five extra patients weekly, while 49% report saving at least 132 hours per year.
AI tools are linked to fewer potential medical errors, better work-life balance and reduced stress. 74% report increased use of AI tools and 73% see time-savings, yet around eight in ten cite limited or inconsistent AI training, highlighting ongoing readiness and governance gaps.
Philips (NYSE:PHG) released its Future Health Index 2026, showing AI already delivering measurable impact in healthcare. Based on responses from over 2,000 clinicians and 20,000 patients across 10 countries, the report highlights time savings, workflow benefits and training gaps.
Key findings include AI saving clinicians on average 132 hours a year (over 16 working days), with 50% gaining capacity to see about eight more patients weekly. 65% report greater confidence in decisions and 49% less work-related stress, while 39% say AI has identified or helped prevent potential medical errors at least three times in three months. However, 70% of clinicians cite inadequate, inconsistent or unavailable AI training, and fragmented IT infrastructure still limits broader deployment.
Philips (NYSE: PHG) and WellSpan Health announced a seven-year strategic alliance covering Central Pennsylvania and Northern Maryland. The collaboration combines research, co-development and a long-term commercial agreement.
It includes AI-enabled imaging and diagnostics, co-created products, and lifecycle-managed Philips equipment across 12 WellSpan hospitals and outpatient sites to enhance care and operational efficiency.
Philips (NYSE: PHG) received FDA 510(k) clearance for Elevate Plus on its EPIQ Elite and Affiniti ultrasound systems, adding AI-powered workflow and imaging enhancements. Elevate Plus, which also has CE Mark, offers Auto Measure Abdomen with over 93% accuracy and reported scanning time reductions of up to 30%.
Integrated Koios AI decision support enables rapid Bi-RADS and Ti-RADS lesion classification, while new imaging tools like XRes Pro+ and Super Res MVI Pro support clearer visualization. A modular, upgradable platform aims to extend system lifespan and support remote updates and tele-health workflows.